查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2033141

癌症免疫療法市場規模、佔有率、趨勢和預測：按治療方法、應用、最終用戶和地區分類（2026-2034 年）

Cancer Immunotherapy Market Size, Share, Trends and Forecast by Therapy Type, Application, End User, and Region, 2026-2034
出版日期: | 出版商: IMARC | 英文 135 Pages | 商品交期: 2-3個工作天內

價格

2025年全球癌症免疫療法市場規模為1,405億美元。展望未來，IMARC Group預測，該市場在2026年至2034年間將以7.89%的複合年成長率成長，到2034年達到2,841億美元。目前，北美市場佔據主導地位，預計到2025年將佔據超過45.2%的市場。推動市場成長的主要因素包括癌症患者數量的增加、政府的支持措施以及醫療保險的普及。

全球癌症免疫療法市場分析：

市場主要促進因素：營養不良和接觸有害物質導致癌症患者數量增加，是推動市場成長的主要因素之一。此外，全球大眾對各種癌症治療方法的認知不斷提高，也促進了市場成長。

市場主要趨勢：醫療保險的普及和便利獲取，以及醫療保健支出的成長，為產業投資者創造了極具吸引力的成長機會。此外，對副作用較少的先進治療方法（例如免疫療法）的需求不斷成長，也為市場帶來了光明的前景。

區域趨勢：從區域來看，市場分為北美、亞太、歐洲、拉丁美洲以及中東和非洲，其中北美目前在全球市場佔據主導地位。

競爭格局：全球癌症免疫療法市場的主要參與者包括安進、Astra Zeneca、拜耳、百時美施貴寶、禮來、羅氏、葛蘭素史克、強生、默克、諾華、輝瑞、賽諾菲和Sigen。

挑戰與機會：治療反應因腫瘤類型而異。然而，免疫療法可能無效，尤其是在「冷Tamoa」（免疫反應低下的腫瘤）的情況下，這表明存在抗藥性。因此，內源性或後天性抗藥性的出現，對免疫療法領域的市場參與者而言，既是巨大的挑戰，也是巨大的機會。

全球癌症免疫療法市場趨勢

癌症患者數量增加

全球癌症病例的不斷增加是癌症免疫療法市場的主要驅動力。根據國際癌症研究機構（IARC）估計，2020年全球約有1,929萬例癌症病例，預計2030年將增加至2,458萬例。癌症病例的顯著成長推動了對免疫療法等有效治療方法的需求。根據GLOBOCAN統計，2020年美國約有2281658例新確診癌症病例，其中612390例死亡病例完全歸因於癌症。此外，肺癌和乳癌是人群中最常見的兩種癌症。根據加拿大癌症協會（CCS）統計，2020年約有29,800名加拿大人被診斷出罹患肺癌，佔所有新發癌症病例的13%。此外，預計2020年約有21,200名加拿大人死於肺癌，佔當年所有癌症死亡人數的25%。這表明人們對更有效、更先進的癌症免疫療法的需求日益成長。因此，對有效且永續的癌症治療日益成長的需求預計將為整個市場帶來巨大的成長機會。

新免疫療法核准增加

主要市場參與者正大力投資研發，以開發和推出更先進、更有效的免疫療法。根據美國國家臨床試驗註冊中心（NCT）的數據，截至2020年9月8日，全球已有超過1,000項臨床試驗正在進行，旨在開發用於癌症治療的免疫療法。此外，許多國家的政府和監管機構正在努力加快新免疫療法的核准流程，預計這將進一步推動市場成長。例如，根據美國癌症研究協會（AACR）發表的報導，美國食品藥物管理局（FDA）於2023年7月核准了quizartinib（Vanflyta）用於治療所有階段的新診斷急性骨髓性白血病（AML）。 Quizartinib靶向FLT3激酶，該激酶在大約三分之一的AML病例中發生突變。同樣，2021年5月，美國FDA核准安進公司的LUMAKRAS（sotrasib）用於治療攜帶KRAS G12C突變的局部進行性或轉移性非小細胞肺癌（NSCLC）患者。 LUMAKRAS是目前首個也是迄今唯一獲準的NSCLC標靶治療。這些進展有望在未來幾年推動癌症免疫療法市場的成長。

製藥公司與研究機構之間的夥伴關係和合作研究

各大公司正積極推行各項策略性措施推出新產品，為整體市場帶來光明前景。例如，2023年9月，Imatics與Moderna達成策略合作，共同開發癌症療法。該合作包括評估Imatics的在臨床實驗藥物PRAME203 TCRT與Moderna的mRNA癌症疫苗MARTE的聯合療法。此外，2023年8月，富邦生物科技有限公司與上海恆力生物技術有限公司簽署策略合作協議，加速新型免疫療法的研發。同樣，2023年12月，德國生物醫學創新中心（BioMed X）宣布與日本製藥公司小野藥品工業株式會社開展一項新的合作研究項目，旨在利用嗜中性白血球的抗腫瘤作用，設計新一代免疫療法。包括安進、Astra Zeneca、拜耳和禮來公司在內的多家市場參與者也積極併購活動。這些公司正透過併購活動拓展企業發展並進入新市場。預計這將推動預測期內癌症免疫療法市場的收入成長。

市場區隔:

本報告分析了全球癌症免疫療法市場各細分領域的關鍵趨勢，並對2026年至2034年進行了全球、區域和國家層面的預測。市場按治療方法類型、應用和最終用戶進行細分。

依治療方法分類：

  • 單株抗體
  • 癌症疫苗
  • 查核點抑制劑
  • 免疫調節劑
  • 其他

目前，單株抗體佔了大部分市場。

單株抗體研發投入的增加，為癌症治療領域的企業發展開闢了新的途徑。單株抗體因其對多種癌症的治療效果而受到廣泛研究。例如，2023年8月，FDA核准Talvey用於治療至少接受四種既往療法（包括蛋白酶體抑制劑、免疫調節劑和核准CD38單株抗體）的復發或難治性多發性骨髓瘤成人患者。

按用途細分：

  • 肺癌
  • 乳癌
  • 結腸癌
  • 惡性黑色素瘤
  • 攝護腺癌
  • 頭頸癌
  • 其他

其中，肺癌目前佔據了壓倒性的市場。

根據癌症免疫療法市場概覽，肺癌領域佔據了最大的市場。這主要歸因於肺癌發生率的不斷上升、免疫療法的日益普及以及大量在臨床實驗藥物的存在。此外，產品核准數量的增加和新產品的上市也為市場帶來了良好的前景。例如，2023年11月，美國食品藥物管理局（FDA）批准了Augtyro（百時美施貴寶公司）的核准repotrectinib用於治療局部進行性或轉移性非小細胞肺癌（NSCLC）。

按最終用戶細分：

  • 醫院
  • 癌症研究中心
  • 診所
  • 其他

醫院佔據最大的市場。

癌症患者人數的增加、治療率的提高以及提供免疫療法的醫院數量的成長，都導致了住院人數的上升。免疫療法在癌症治療醫院中正變得越來越普遍。根據美國國家癌症研究所2023年4月發表的報導，美國25%的癌症患者在醫院去世，62%的患者在生命最後一個月內至少因癌症治療住院一次。

按地區分類：

  • 北美洲
  • 我們
  • 加拿大
  • 亞太地區
  • 中國
  • 日本
  • 印度
  • 韓國
  • 澳洲
  • 印尼
  • 其他
  • 歐洲
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙
  • 俄羅斯
  • 其他
  • 拉丁美洲
  • 巴西
  • 墨西哥
  • 其他
  • 中東和非洲

目前，北美在全球市場佔據主導地位。

此外，本報告對所有主要區域市場進行了全面分析，包括北美（美國和加拿大）、亞太地區（中國、日本、印度、韓國、澳洲、印尼等）、歐洲（德國、法國、英國、義大利、西班牙、俄羅斯等）、拉丁美洲（巴西、墨西哥等）以及中東和非洲。報告指出，北美（美國和加拿大）是癌症免疫療法最大的市場。

該地區的成長歸功於癌症患者數量的增加、生物資訊學工具的進步以及政府的利好政策。根據GLOBOCAN統計，2020年美國新增癌症病例約2,281,658例，癌症死亡人數達612,390人。此外，該地區許多大型企業的存在也促進了市場成長。根據Elsevier Ltd.發表的報導，美國國家癌症研究所（NCI）於2023年4月發布了“可預見的國家癌症計劃”，該指南藍圖和行動方案，旨在改善癌症患者護理的各個階段。

競爭格局：

這份市場調查報告對競爭格局進行了全面分析，並詳細介紹了主要參與者的情況。市場主要參與者包括：

  • 安進
  • Astra Zeneca公司
  • 拜耳股份公司
  • 百時美施貴寶
  • 禮來公司
  • F. Hoffmann-La Roche 有限公司
  • GSK plc
  • 強生公司
  • 默克集團
  • 諾華公司
  • 輝瑞
  • 賽諾菲
  • 錫根有限公司

本報告解答的主要問題

1. 什麼是癌症免疫療法？

2. 癌症免疫療法市場規模有多大？

3. 2026年至2034年全球癌症免疫療法市場的預期成長率為何？

4. 推動全球癌症免疫療法市場發展的主要因素是什麼？

5. 在全球癌症免疫療法市場中，依治療方法分類，主要細分市場有哪些？

6. 從應用領域來看，全球癌症免疫療法市場中最大的細分市場是哪一領域？

7. 從最終用戶的角度來看，全球癌症免疫療法市場的主要細分市場有哪些？

8. 全球癌症免疫療法市場的主要區域有哪些？

9. 全球癌症免疫療法市場的主要參與者/公司有哪些？

目錄

第1章：序言

第2章：調查方法

  • 調查目的
  • 相關利益者
  • 數據來源
    • 主要訊息
    • 次要訊息
  • 市場估值
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第3章執行摘要

第4章：引言

第5章：全球癌症免疫療法市場

  • 市場概覽
  • 市場表現
  • 新冠疫情的影響
  • 市場預測

第6章 市場區隔：依治療方法分類

  • 單株抗體
  • 癌症疫苗
  • 查核點抑制劑
  • 免疫調節藥物
  • 其他

第7章 市場區隔：依應用領域分類

  • 肺癌
  • 乳癌
  • 結腸癌
  • 黑色素瘤
  • 攝護腺癌
  • 頭頸癌
  • 其他

第8章 市場區隔：依最終用戶分類

  • 醫院
  • 癌症研究中心
  • 診所
  • 其他

第9章 市場區隔：依地區分類

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲

第10章 SWOT 分析

第11章：價值鏈分析

第12章：波特五力分析

第13章：價格分析

第14章 競爭格局

  • 市場結構
  • 大公司
  • 主要公司簡介
    • Amgen Inc
    • AstraZeneca plc
    • Bayer AG
    • Bristol-Myers Squibb Company
    • Eli Lilly and Company
    • F. Hoffmann-La Roche Ltd
    • GSK plc.
    • Johnson & Johnson
    • Merck & Co., Inc.
    • Merck KGaA
    • Novartis AG
    • Pfizer Inc.
    • Sanofi SA
Product Code: SR112026A5095

The global cancer immunotherapy market size was valued at USD 140.5 Billion in 2025. Looking forward, IMARC Group estimates the market to reach USD 284.1 Billion by 2034, exhibiting a CAGR of 7.89% from 2026-2034. North America currently dominates the market, holding a market share of over 45.2% in 2025. The growing number of cancer cases, favorable government initiatives, and easy availability of medical insurance represent some of the key factors driving the market.

Global Cancer Immunotherapy Market Analysis:

Major Market Drivers: The increasing cases of cancer on account of a poor balanced diet and consumption of toxic substances is one of the primary factors driving the growth of the market. In addition to this, the growing awareness about various cancer treatment options among the masses across the world is also contributing to the market growth.

Key Market Trends: The wide availability and easy access to medical insurance, along with the increasing healthcare expenditures, is offering lucrative growth opportunities to industry investors. In addition to this, the emerging preference for advanced treatment solutions with fewer side effects, like immunotherapy, is creating a positive outlook for the market.

Geographical Landscape: On a regional level, the market has been classified into North America, Asia-Pacific, Europe, Latin America, and Middle East and Africa, where North America currently dominates the global market.

Competitive Landscape: Some of the leading players in the global cancer immunotherapy market include Amgen Inc., AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche AG, GSK plc, Johnson & Johnson, Merck KGaA, Novartis AG, Pfizer Inc., Sanofi S.A, and Seagen Inc., among others.

Challenges and Opportunities: Different tumor types respond differently. However, in some cases, especially cold tumors immunotherapy is unresponsive, suggesting the presence of resistance. Hence, the development of intrinsic or acquired resistance is a big challenge as well as a significant opportunity for the market players in the immunotherapy field.

Global Cancer Immunotherapy Market Trends

Increasing Prevalence of Cancer

The rising number of cancer cases across the world is primarily driving the market for cancer immunotherapies. The International Agency for Research on Cancer (IARC) estimated that, in the year 2020, there were about 19.29 million cancer cases. These cases are projected to increase to 24.58 million cases by 2030. Such a substantial growth in cancer cases is augmenting the demand for effective treatment solutions like immunotherapies. According to GLOBOCAN, in 2020, there were approximately 2,281,658 new cancer cases diagnosed and 612,390 deaths due to cancer alone in the United States. In addition to this, lung cancer and breast cancer are two of the most common cancers found among individuals. The Canadian Cancer Society (CCS) stated that in 2020, nearly 29,800 Canadians were diagnosed with lung cancer, which accounted for 13% of all new cancer cases. About 21,200 Canadians were expected to die from lung cancer, which represented 25% of all cancer deaths in 2020. This indicates an inflating need for effective and more advanced cancer immunotherapy. Thus, the increasing demand for effective and lasting cancer treatment is anticipated to offer lucrative growth opportunities to the overall market.

Rising Approval of Novel Immunotherapies

Various key market players are extensively investing in research and development activities to develop and introduce advanced and more effective immunotherapies. According to the National Clinical Trials (NCT) Registry, as of September 8, 2020, there were more than 1,000 ongoing clinical trials across the world for the development of cancer treatment with immune-based therapies. Moreover, government authorities and concerned regulators of numerous nations are taking initiatives to expedite the approval process of novel immunotherapies, which is anticipated to further catalyze the market growth. For instance, according to an article published by the American Association for Cancer Research, in July 2023, the FDA approved quizartinib (Vanflyta) for treating different phases of newly diagnosed acute myeloid leukemia (AML). Quizartinib focuses on FLT3, a kinase that goes twisted in about one-third of AML cases. Similarly, in May 2021, the US FDA approved Amgen's LUMAKRAS (Sotorasib) for the treatment of patients with KRAS G12C, which involves mutated locally advanced or metastatic non-small cell lung cancer (NSCLC). LUMAKRAS is the first and only targeted treatment for NSCLC. Such developments are expected to propel the cancer immunotherapy market growth in the coming years.

Partnerships and Collaborations between Pharmaceuticals and Research Institutions

Various Strategic initiatives are being undertaken by major players to launch new products, which is creating a positive outlook for the overall market. For instance, in September 2023, Immatics and Moderna strategically collaborated to develop Oncology Therapeutics. The collaboration includes an assessment of Immatics investigational PRAME203 TCRT in combination with the MARTE mRNA cancer vaccine being developed by Moderna. Moreover, in August 2023, FBD Biologics Limited and Shanghai Henlius Biotech, Inc. entered into a strategic collaboration to boost the development of new immunotherapies. Similarly, in December 2023, BioMed X, a German research institution, announced a new joint research project with Ono Pharmaceutical Co. Ltd, a Japanese pharmaceutical company, to design next-generation immunotherapies by leveraging the antitumor effects of neutrophils. Several market players, such as Amgen Inc., AstraZeneca plc, Bayer AG, and Eli Lilly and Company, are involved in merger and acquisition activities. Through M&A activity, these companies are expanding their geographic reach and entering new territories. This, in turn, is projected to bolster the cancer immunotherapy market revenue over the forecasted period.

Market Segmentation:

This report provides an analysis of the key trends in each segment of the global cancer immunotherapy market, along with forecast at the global, regional, and country levels from 2026-2034. The market has been categorized based on therapy type, application, and end user.

Breakup by Therapy Type:

  • Monoclonal Antibodies
  • Cancer Vaccines
  • Checkpoint Inhibitors
  • Immunomodulators
  • Others

Currently, monoclonal antibodies hold the majority of the total market share

Increasing investment for research and development activities of monoclonal antibodies is opening new avenues for the growth of companies in the oncology therapeutics space. Monoclonal antibodies are extensively being studied for their therapeutic effects against various types of cancers. For instance, in August 2023, FDA approved Talvey to treat adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of treatment, including proteasome inhibitors, immunomodulatory agents and an antiCD38 monoclonal antibody.

Breakup by Application:

  • Lung Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Melanoma
  • Prostate Cancer
  • Head and Neck Cancer
  • Others

Among these, lung cancer currently exhibits a clear dominance in the market

According to cancer immunotherapy market overview, the lung cancer segment accounted for the largest revenue share in the market. This can be attributed to the increasing prevalence of lung malignancies, the escalating adoption of immunotherapy, and the presence of a robust pipeline of investigational candidates. Furthermore, rising product approval and new product launches also providing a positive outlook to the market. For instance, in November 2023, the US Food and Drug Administration (FDA) granted marketing authorizations to Augtyro (Bristol, Inc.) for the treatment of locally refractory or metastatic Non-Small Cell Lung Cancer (NSCLC) with Repotrectinib.

Breakup by End User:

  • Hospitals
  • Cancer Research Centers
  • Clinics
  • Others

Hospitals account for the largest market share

Growing cases of cancer, increasing treatment rates, along with a large number of hospitals offering immunotherapies are contributing to a rise in the number of patients admitted to a hospital. To treat cancer, hospitals are increasingly utilizing immunotherapies. According to an article published by the National Cancer Institute, in April 2023, in the U.S. 25% of patients died in a hospital, with 62% hospitalized at least once in the last month of life for the cancer treatments.

Breakup by Regional:

  • North America
  • United States
  • Canada
  • Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa

North America currently dominates the global market.

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America (the United States and Canada) was the largest market for cancer immunotherapy.

The growth in the region can be attributed to the growing number of patients suffering from cancer, the rising development of bioinformatic tools, and favorable government initiatives. According to GLOBOCAN, in the US, there were an estimated 2,281,658 new cancer cases diagnosed and 612,390 deaths due to cancer in the year 2020. Moreover, the presence of key players in this region is also contributing to the growth of the market. According to an article published by Elsevier Ltd., in April 2023, the US National Cancer Institute published its expected national cancer plan, a roadmap, and calls to action on improving all stages of care for those suffering from cancer.

Competitive Landscape:

The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

  • Amgen Inc.
  • AstraZeneca plc
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • GSK plc
  • Johnson & Johnson
  • Merck KGaA
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A
  • Seagen Inc.

Key Questions Answered in This Report

1. What is cancer immunotherapy?

2. How big is the cancer immunotherapy market?

3. What is the expected growth rate of the global cancer immunotherapy market during 2026-2034?

4. What are the key factors driving the global cancer immunotherapy market?

5. What is the leading segment of the global cancer immunotherapy market based on therapy type?

6. What is the leading segment of the global cancer immunotherapy market based on application?

7. What is the leading segment of the global cancer immunotherapy market based on end user?

8. What are the key regions in the global cancer immunotherapy market?

9. Who are the key players/companies in the global cancer immunotherapy market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Cancer Immunotherapy Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Therapy Type

  • 6.1 Monoclonal Antibodies
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Cancer Vaccines
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Checkpoint Inhibitors
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Immunomodulators
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Others
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast

7 Market Breakup by Application

  • 7.1 Lung Cancer
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Breast Cancer
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Colorectal Cancer
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Melanoma
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Prostate Cancer
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast
  • 7.6 Head and Neck Cancer
    • 7.6.1 Market Trends
    • 7.6.2 Market Forecast
  • 7.7 Others
    • 7.7.1 Market Trends
    • 7.7.2 Market Forecast

8 Market Breakup by End User

  • 8.1 Hospitals
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Cancer Research Centers
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Clinics
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Others
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Amgen Inc
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 AstraZeneca plc
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 Bayer AG
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Bristol-Myers Squibb Company
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 Eli Lilly and Company
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 F. Hoffmann-La Roche Ltd
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 SWOT Analysis
    • 14.3.7 GSK plc.
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 Johnson & Johnson
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9 Merck & Co., Inc.
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
      • 14.3.9.4 SWOT Analysis
    • 14.3.10 Merck KGaA
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
      • 14.3.10.4 SWOT Analysis
    • 14.3.11 Novartis AG
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
      • 14.3.11.3 Financials
      • 14.3.11.4 SWOT Analysis
    • 14.3.12 Pfizer Inc.
      • 14.3.12.1 Company Overview
      • 14.3.12.2 Product Portfolio
      • 14.3.12.3 Financials
      • 14.3.12.4 SWOT Analysis
    • 14.3.13 Sanofi S.A
      • 14.3.13.1 Company Overview
      • 14.3.13.2 Product Portfolio
      • 14.3.13.3 Financials
      • 14.3.13.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Cancer Immunotherapy Market: Major Drivers and Challenges
  • Figure 2: Global: Cancer Immunotherapy Market: Sales Value (in Billion USD), 2020-2025
  • Figure 3: Global: Cancer Immunotherapy Market Forecast: Sales Value (in Billion USD), 2026-2034
  • Figure 4: Global: Cancer Immunotherapy Market: Breakup by Therapy Type (in %), 2025
  • Figure 5: Global: Cancer Immunotherapy Market: Breakup by Application (in %), 2025
  • Figure 6: Global: Cancer Immunotherapy Market: Breakup by End User (in %), 2025
  • Figure 7: Global: Cancer Immunotherapy Market: Breakup by Region (in %), 2025
  • Figure 8: Global: Cancer Immunotherapy (Monoclonal Antibodies) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 9: Global: Cancer Immunotherapy (Monoclonal Antibodies) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 10: Global: Cancer Immunotherapy (Cancer Vaccines) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 11: Global: Cancer Immunotherapy (Cancer Vaccines) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 12: Global: Cancer Immunotherapy (Checkpoint Inhibitors) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 13: Global: Cancer Immunotherapy (Checkpoint Inhibitors) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 14: Global: Cancer Immunotherapy (Immunomodulators) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 15: Global: Cancer Immunotherapy (Immunomodulators) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 16: Global: Cancer Immunotherapy (Other Therapy Types) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 17: Global: Cancer Immunotherapy (Other Therapy Types) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 18: Global: Cancer Immunotherapy (Lung Cancer) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 19: Global: Cancer Immunotherapy (Lung Cancer) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 20: Global: Cancer Immunotherapy (Breast Cancer) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 21: Global: Cancer Immunotherapy (Breast Cancer) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 22: Global: Cancer Immunotherapy (Colorectal Cancer) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 23: Global: Cancer Immunotherapy (Colorectal Cancer) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 24: Global: Cancer Immunotherapy (Melanoma) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 25: Global: Cancer Immunotherapy (Melanoma) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 26: Global: Cancer Immunotherapy (Prostate Cancer) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 27: Global: Cancer Immunotherapy (Prostate Cancer) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 28: Global: Cancer Immunotherapy (Head and Neck Cancer) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 29: Global: Cancer Immunotherapy (Head and Neck Cancer) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 30: Global: Cancer Immunotherapy (Other Applications) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 31: Global: Cancer Immunotherapy (Other Applications) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 32: Global: Cancer Immunotherapy (Hospitals) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 33: Global: Cancer Immunotherapy (Hospitals) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 34: Global: Cancer Immunotherapy (Cancer Research Centers) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 35: Global: Cancer Immunotherapy (Cancer Research Centers) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 36: Global: Cancer Immunotherapy (Clinics) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 37: Global: Cancer Immunotherapy (Clinics) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 38: Global: Cancer Immunotherapy (Other End Users) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 39: Global: Cancer Immunotherapy (Other End Users) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 40: North America: Cancer Immunotherapy Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 41: North America: Cancer Immunotherapy Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 42: United States: Cancer Immunotherapy Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 43: United States: Cancer Immunotherapy Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 44: Canada: Cancer Immunotherapy Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 45: Canada: Cancer Immunotherapy Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 46: Asia-Pacific: Cancer Immunotherapy Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 47: Asia-Pacific: Cancer Immunotherapy Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 48: China: Cancer Immunotherapy Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 49: China: Cancer Immunotherapy Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 50: Japan: Cancer Immunotherapy Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 51: Japan: Cancer Immunotherapy Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 52: India: Cancer Immunotherapy Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 53: India: Cancer Immunotherapy Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 54: South Korea: Cancer Immunotherapy Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 55: South Korea: Cancer Immunotherapy Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 56: Australia: Cancer Immunotherapy Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 57: Australia: Cancer Immunotherapy Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 58: Indonesia: Cancer Immunotherapy Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 59: Indonesia: Cancer Immunotherapy Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 60: Others: Cancer Immunotherapy Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 61: Others: Cancer Immunotherapy Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 62: Europe: Cancer Immunotherapy Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 63: Europe: Cancer Immunotherapy Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 64: Germany: Cancer Immunotherapy Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 65: Germany: Cancer Immunotherapy Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 66: France: Cancer Immunotherapy Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 67: France: Cancer Immunotherapy Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 68: United Kingdom: Cancer Immunotherapy Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 69: United Kingdom: Cancer Immunotherapy Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 70: Italy: Cancer Immunotherapy Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 71: Italy: Cancer Immunotherapy Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 72: Spain: Cancer Immunotherapy Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 73: Spain: Cancer Immunotherapy Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 74: Russia: Cancer Immunotherapy Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 75: Russia: Cancer Immunotherapy Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 76: Others: Cancer Immunotherapy Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 77: Others: Cancer Immunotherapy Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 78: Latin America: Cancer Immunotherapy Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 79: Latin America: Cancer Immunotherapy Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 80: Brazil: Cancer Immunotherapy Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 81: Brazil: Cancer Immunotherapy Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 82: Mexico: Cancer Immunotherapy Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 83: Mexico: Cancer Immunotherapy Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 84: Others: Cancer Immunotherapy Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 85: Others: Cancer Immunotherapy Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 86: Middle East and Africa: Cancer Immunotherapy Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 87: Middle East and Africa: Cancer Immunotherapy Market: Breakup by Country (in %), 2025
  • Figure 88: Middle East and Africa: Cancer Immunotherapy Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 89: Global: Cancer Immunotherapy Industry: SWOT Analysis
  • Figure 90: Global: Cancer Immunotherapy Industry: Value Chain Analysis
  • Figure 91: Global: Cancer Immunotherapy Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Cancer Immunotherapy Market: Key Industry Highlights, 2025 and 2034
  • Table 2: Global: Cancer Immunotherapy Market Forecast: Breakup by Therapy Type (in Million USD), 2026-2034
  • Table 3: Global: Cancer Immunotherapy Market Forecast: Breakup by Application (in Million USD), 2026-2034
  • Table 4: Global: Cancer Immunotherapy Market Forecast: Breakup by End User (in Million USD), 2026-2034
  • Table 5: Global: Cancer Immunotherapy Market Forecast: Breakup by Region (in Million USD), 2026-2034
  • Table 6: Global: Cancer Immunotherapy Market: Competitive Structure
  • Table 7: Global: Cancer Immunotherapy Market: Key Players